Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) resulting from allegations that AVROBIO may have issued materially misleading business information to the investing public.

If you purchased AVROBIO securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased AVROBIO securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On May 3, 2021, before market hours, AVROBIO issued a press release entitled “AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease” which announced that “AVROBIO can no longer pursue an accelerated approval pathway for AVR-RD-01 with the FAB-GT trial as currently designed[.]”

On this news, AVROBIO share prices fell $2.20 per share, or 18%, to close at $9.48 on May 3, 2021.

公司名称: AVROBIO, Inc.
股票代号: ACRO
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。


Scroll to Top